Advances in genomics technologies have had a major impact on the depth, breadth, and coverage of genomic data being generated as a part of cancer research initiatives. Genomic approaches to cancer research can be used to elucidate mechanisms of cancer, drive therapeutic target discovery, enhance biomarker discovery, and stratify patients in clinical trials.
Genomics in Cancer Research
Cancer researchers can use whole genome, exome, and targeted amplicon next generation sequencing approaches to characterize cancer-associated mutations and other biomarkers.
Clinical trial researchers can use next generation sequencing cancer panels to identify known cancer biomarkers within a patient population to accurately identify subsets of the population with increased sensitivity to the therapeutic being tested.
Synthetic biologists are testing nucleotide and amino acid-level variations in target genes to gain understanding of protein function in oncogenesis.
GENEWIZ offers a number of genomics solutions to assist in cancer research and discovery at different stages of your research.
GENEWIZ’s proprietary cancer panels offer a massively-parallel approach to known cancer-related gene mutation characterization. OncoGxOne panels are currently available for 19 different cancer types. With quick turnaround and the high sensitivity afforded by MiSeq and HiSeq technologies, our OncoGxOne service quickly and comprehensively catalogs the mutations within known cancer-associated genes specific to each cancer type.
We offer a range of Sanger sequencing options available to meet the cancer researcher’s basic toolkit needs. From PCR purification to direct-colony sequencing, GENEWIZ’s fast turnaround and high-quality data will accelerate the pace of your cancer-related sequence confirmation needs.
Gene Synthesis services offer cancer researchers a way to characterize the effects of genomic mutations upon the mechanisms of cellular functions. An alternative to molecular cloning, gene synthesis affords cancer researchers a quicker way to generate constructs to test in vitro the impact of nucleotide and amino acid-level changes on the mechanisms of cancer.